AU2015353549A1 - Crystalline forms of PARP inhibitors - Google Patents

Crystalline forms of PARP inhibitors Download PDF

Info

Publication number
AU2015353549A1
AU2015353549A1 AU2015353549A AU2015353549A AU2015353549A1 AU 2015353549 A1 AU2015353549 A1 AU 2015353549A1 AU 2015353549 A AU2015353549 A AU 2015353549A AU 2015353549 A AU2015353549 A AU 2015353549A AU 2015353549 A1 AU2015353549 A1 AU 2015353549A1
Authority
AU
Australia
Prior art keywords
compound
crystalline form
depicted
salt
further characterized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015353549A
Other languages
English (en)
Inventor
Stephen J. Bierlmaier
Ralph C. Haltiwanger
Martin J. Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of AU2015353549A1 publication Critical patent/AU2015353549A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/06—Glycolic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2015353549A 2014-11-26 2015-11-25 Crystalline forms of PARP inhibitors Abandoned AU2015353549A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084652P 2014-11-26 2014-11-26
US62/084,652 2014-11-26
PCT/US2015/062572 WO2016086080A1 (en) 2014-11-26 2015-11-25 Crystalline forms of parp inhibitors

Publications (1)

Publication Number Publication Date
AU2015353549A1 true AU2015353549A1 (en) 2017-06-01

Family

ID=54849709

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015353549A Abandoned AU2015353549A1 (en) 2014-11-26 2015-11-25 Crystalline forms of PARP inhibitors

Country Status (13)

Country Link
US (1) US10150772B2 (cg-RX-API-DMAC7.html)
EP (1) EP3224259A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017535564A (cg-RX-API-DMAC7.html)
KR (1) KR20170088894A (cg-RX-API-DMAC7.html)
CN (1) CN107207511A (cg-RX-API-DMAC7.html)
AU (1) AU2015353549A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017010588A2 (cg-RX-API-DMAC7.html)
CA (1) CA2967828A1 (cg-RX-API-DMAC7.html)
HK (1) HK1244006A1 (cg-RX-API-DMAC7.html)
IL (1) IL252162A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017006679A (cg-RX-API-DMAC7.html)
RU (1) RU2017120655A (cg-RX-API-DMAC7.html)
WO (1) WO2016086080A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
WO2008063644A1 (en) * 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク． 多環系化合物の新規形態

Also Published As

Publication number Publication date
JP2017535564A (ja) 2017-11-30
CN107207511A (zh) 2017-09-26
BR112017010588A2 (pt) 2018-05-15
US10150772B2 (en) 2018-12-11
MX2017006679A (es) 2018-07-06
WO2016086080A1 (en) 2016-06-02
EP3224259A1 (en) 2017-10-04
CA2967828A1 (en) 2016-06-02
IL252162A0 (en) 2017-07-31
RU2017120655A3 (cg-RX-API-DMAC7.html) 2018-12-14
KR20170088894A (ko) 2017-08-02
US20170267683A1 (en) 2017-09-21
RU2017120655A (ru) 2018-12-14
HK1244006A1 (zh) 2018-07-27

Similar Documents

Publication Publication Date Title
Lin et al. Preparation, Characterization, and Evaluation of Dipfluzine–Benzoic Acid Co-crystals with Improved Physicochemical Properties: Lin, Yang, Yang and Wang
TW201109334A (en) PLK inhibitor salts
AU2017373239B2 (en) Crystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereof
US10370406B2 (en) Salts and polymorphs of SCY-078
IL298518B1 (en) Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation
IL309263A (en) Crystalline form of tolbrotinib, method of preparation and use thereof
Paulekuhn et al. Salt screening and characterization for poorly soluble, weak basic compounds: case study albendazole
EP3057965A1 (en) Salt and crystal forms of plk-4 inhibitor
AU2014336929A1 (en) Salt and crystal forms of PLK-4 inhibitor
JP5997162B2 (ja) アプレピタントｌ−プロリン組成物および共結晶
US20240116925A1 (en) Salt of nitrogen-containing fused heterocyclic compound or crystal form thereof, and preparation method therefor, pharmaceutical composition thereof, and use thereof
US10150772B2 (en) Crystalline forms of PARP inhibitors
WO2020025449A1 (en) Highly stable crystalline eltrombopag monoethanolamine salt form d1
EP2922838B1 (en) Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
US20240409501A1 (en) Cyrstalline forms of rip1 inhibitor
WO2021176216A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
HK40079381A (en) Novel salts and polymorphs of scy-078
KR20260066052A (ko) 베주클라스티닙의 결정형, 이의 제조방법 및 이의 용도
CA2944150A1 (en) Polymorphic forms and co-crystals of a c-met inhibitor
HK40081980B (en) Organic acid addition salts of s-pindolol
HK40081980A (en) Organic acid addition salts of s-pindolol
WO2019105082A1 (zh) Galunisertib的晶型及其制备方法和用途
HK1187554B (en) Aprepitant l-proline composition and cocrystal

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period